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T  lymphocytes immune to tumor-associated antigens  (TAA)  on syngeneic tumor 
ceils  can  readily  be shown  to  lyse  tumor  cells  in  vitro  and  inhibit  the  growth  of 
transplanted tumors if administered shortly before, with, or shortly after the inocula- 
tion of tumor.  However, after a  tumor has become established in the host, therapy 
with adoptively transferred lymphocytes alone has generally been ineffective (1). The 
limited ability of adoptive immunotherapy to eradicate established tumors presum- 
ably reflects consequences  of a  growing  tumor, such  as a  large tumor burden  and 
induction  of suppressor cells or suppressor factors in the host  (2,  3).  Thus, immuno- 
therapeutic approaches that include  modifying this underlying host-tumor relation- 
ship have been more successful. For example, in therapy of established locally growing 
rat and murine fibrosarcomas, the efficacy of immune T  cells is enhanced  if, before 
inoculation of the tumors, the host has been irradiated or rendered T  cell deficient 
(3,  4).  Several  immunotherapy  models  have  been  developed  in  our  laboratory  in 
which  mice  with  established  disseminated  syngeneic  leukemias  can  be  effectively 
treated with a combination of noncurative, nonlethal chemotherapy with cyclophos- 
phamide (CY), 1 followed by adoptively transferred syngeneic immune cells (5-8). In 
these  models,  the  CY  has  a  direct  tumoricidal  effect  (6),  as  well  as  potentially 
facilitating effects on host tumor immunity, and therapy with immune cells without 
CY has no apparent  in vivo anti-tumor effect (5).  In vivo efficacy in such adoptive 
chemoimmunotherapy  (ACIT)  requires  immune T  ceils capable of proliferating in 
the host after adoptive transfer (5,  7), and studies of ACIT of two non-cross-reactive 
tumors of C57BL/6 origin have confirmed that the lymphocytes must be specifically 
immune to the relevant tumor (8). 
The cellular mechanisms by which  adoptively transferred T  cells mediate tumor 
destruction in vivo might be further elucidated by determination of the functional T 
cell subsets operative in immunotherapy. Although the end results might reflect direct 
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tumor lysis by infused  cytotoxic donor cells,  comparisons of the  ability  of immune 
lymphoeytes  to  mediate  in  vitro  tumor  lysis  and  in  vivo  immunotherapy  have 
generally revealed a  poor correlation between these two effector functions  (4, 9,  10). 
Expression of Lyt antigens  has been shown to be useful  for separating  functional  T 
cell subsets  (reviewed in  11,  12).  By negative selection using cytotoxic depletion with 
antibody and complement, T  cells can be operationally separated into Lyt-1+2  -  cells 
containing  the  amplifier,  helper,  and  delayed  type hypersensitivity  (DTH)  effector 
cells,  Lyt-l-2  +  cells  containing  cytotoxic  and  suppressor  cells,  and  an  Lyt-l+2  + 
compartment containing precursors for the other T  cell subsets, as well as a  portion 
of cytotoxic and suppressor effector cells  (11,  12).  In particular,  eytotoxic T  lympho- 
cytes (CTL) to syngeneic tumors appear to reside in both the Lyt-l-2  + and Lyt-l+2  + 
compartments  (13-17).  Therefore,  in  the  present  studies,  the  efficacy  of T  cell 
subpopulations, as distinguished by expression of Lyt antigens, was analyzed in ACIT 
of established murine leukemia and in in vitro assays for the generation and expression 
of cytotoxicity. The results demonstrate that the phenotype of the predominant T  cell 
subset  required  for efficacy in  ACIT is  Lyt-l+2  -, which  is  distinct  from the  T  cell 
phenotypes mediating in Vitro tumor lysis. 
Materials  and Methods 
Mice.  12-16-week-old (BALB/c ×  C57BL/6)F1 mice, denoted CBF1, were obtained from 
The Jackson Laboratory, Bar Harbor,  Maine.  B10.G  (H-2  q)  and AKR/J  (H-2  k)  mice were 
provided by our breeding facility at the Fred Hutchinson Cancer Research Center. 
Tumor.  FBL-3 is a Friend virus-induced leukemia of C57BL/6 origin maintained by serial 
intraperitoneal  transplantation  (>300 generations)  in adult syngeneic mice. CBFa mice were 
sensitized to FBL-3 in vivo by inoculation of two doses of 2 ×  107 irradiated FBL-3 intraperi- 
toneally at 2-wk intervals, and the immune spleen cells were obtained 2-4 wk later. 
ACIT.  This assay, previously described in detail  (5),  consists  of treating mice that  have 
advanced disseminated FBL-3 leukemia with a combination of nonlethal noneurative chemo- 
therapy and adoptivety transferred immune syngeneic cells. CBF1 mice were inoculated with 5 
×  10"FBL on day 0, and treated on day 5, after tumor dissemination had occurred (6), with 
180 mg/kg CY injected intraperitoneally, followed in 5 h by adoptively transferred CBF1 cells. 
Therapy on day 5 with immune cells alone, without prior CY, has no demonstrable anti-tumor 
effect  (5). Studies with non-cross-reactive tumors of C57BL/6 origin have demonstrated that 
therapeutic efficacy in ACIT requires the transfer of specifically immune lymphocytes (8), and 
the degree of prolongation of survival and percentage of cures is proportional to the number of 
immune cells transferred (8, 9). Survival curves in the present studies were constructed from the 
cumulative results of six experiments with mice treated with CY and a dose of 5 ×  106 immune 
CBF1 cells. This cell dose was selected for presentation because CY plus 5 ×  106 unfractionated 
immune cells  significantly prolonged survival  but  did not cure all  mice,  and  thus  was the 
optimal dose for comparisons of the efficacy of subpopulations. In groups of mice not shown, 
which  were  treated  concurrently  with  smaller  numbers  of fractionated  or  unfractionated 
immune cells, survival was proportionately shorter and the percentage of cures was smaller for 
all groups, consistent with the dose-response relationship of the number of immune cells to the 
outcome of therapy reported in these ACIT models (8, 9). 
Cell Depletion with Antibody and Complement (C).  Spleen cells were incubated at 4°C for 30 
min with monoclonal IgM antibody to Thy-1.2, a kind gift of Dr. E. Clark of the University of 
Washington, Seattle, at a dilution of 1:104/106 cells, arsanilate-conjugated monoclonal IgG a- 
Lyt-1 antibody at 0.6 #g/106 cells, or arsanilate-conjugated monoclonal IgG a-Lyt-2 antibody 
at  0.3 #g/106 cells  (Becton, Dickinson & Co., Oxnard, Calif.).  Cells labeled  with arsanilate- 
conjugated antibody were washed and incubated for an additional 30 rain at 4°C with rabbit 
a-arsanilate antibody at  12 #g/106 cells. The cells were washed and  incubated for 45 min at 
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antibodies  were  not  directly  toxic  to  cells,  and  with  the  addition  of C  maximally  lysed 
thymocytes and spleen T  cells. 
In  Vitro Sensitization.  Mixed leukocyte cultures (MLC) and mixed leukocyte-tumor cultures 
(MLTC) were established as described previously (9). Briefly,  60 ×  106 CBFI responder spleen 
cells were euhured for 5 d in flasks containing 20 ml of supplemented 5% fetal calf serum with 
15 ×  108 irradiated stimulator allogeneic spleen cells or 3 ×  106 irradiated FBL-3 tumor cells. 
The potential role of Lyt-I  + T  cells  as helper-amplifier cells  in the generation of in vitro 
cytotoxic responses  was examined by depleting responder cells of Lyt-1  + cells before in vitro 
culture and reconstituting the amplifier function of Lyt-1  + cells by the addition of supernates 
containing interleukin 2 (IL-2).  The supernates, induced by concanavalin A stimulation of rat 
spleen cells, were kindly provided by Dr. S. Gillis  and Dr. C. Henney of the Fred Hutchinson 
Cancer Research Center, and had previously been purified on DEAE to remove coneanavalin 
A,  titered  by  microassay  to  quantify  IL-2  activity,  and  demonstrated  to  reconstitute  the 
amplifier activity of helper T  cells  for in vitro eytotoxic responses  (18,  19). Therefore, CBFt 
spleen cells were depleted of Lyt-1  + cells by treatment with a-Lyt-1 antibody and C before in 
vitro sensitization. At the initiation of 5-d sensitization culture, IL-2-containing supernates were 
added to selected groups at a  final dilution of 1:10, a concentration sufficient to maximally 
support generation of CTL. After 5 d of culture in this IL-2-supplemented medium, cells were 
harvested and washed, and the generation of cytotoxicity was assessed. 
In  Vitro Cytotoxicity.  Responder cells were harvested and tested for cytolytie activity by 4-h 
incubation with 104 chromium-labeled target cells in microtiter plates.  Cytotoxicity is expressed 
as: percent specific  lysis =  100 (A -  B)/(C -  B), with A =  test sample counts per minute, B 
=  spontaneously released  counts per minute, and C  =  total counts per minute. Target cells 
were either FBL tumor cells or blast cells induced by 48 h  incubation of normal spleen cells 
with eoncanavalin A at 2/xg/ml. 
Results 
Analysis of the  Lyt phenotype(s)  of the  T  cells  responsible  for efficacy in  ACIT 
requires the transfer of large numbers of purified T  cells. The availability of high titer 
monoclonal antibodies to Lyt determinants  has recently made such analysis feasible. 
Before using these monoclonal reagents to separate Lyt subpopulations  for immuno- 
therapy, we examined whether these antibodies and selected absorbed rabbit C would 
appropriately delete CTL to alloantigens and syngeneic tumors, which have been well 
characterized  phenotypically by others  using conventional  alloantisera  to  Lyt anti- 
gens. Therefore, CBF1 spleen cells were sensitized to allogeneic spleen cells or syngeneic 
tumor  cells  in  MLC,  and  cytotoxicity was  examined  after  5  d  culture  (Table  I). 
Treatment  of alloreactive effector cells immediately before testing in a 4-h chromium 
release assay (CRA) with et-Thy-1.2 and C  eliminated all cytotoxicity. The majority 
of cytotoxic reactivity was similarly eliminated  by treatment  of effector cells with ct- 
Lyt-2  and  C,  whereas  depletion  of  Lyt-1 ÷  cells  had  only  a  minimal  effect  on 
cytotoxicity. Thus, as defined functionally, alloreactive CTL were predominantly of 
the Lyt-l-2  + phenotype. 
CTL  that  are  specific  for syngeneic  tumor  can  be  readily  generated  by in  vitro 
sensitization of in vivo-primed spleen cells (8, 9). For this analysis, tumor-primed cells 
were obtained  from spleens of CBF1 mice that had previously been inoculated twice 
with  irradiated  FBL, because these spleen  cells subsequently  served  as the source of 
donor immune cells in adoptive immunotherapy. CBFx cells from nonimmune mice 
did not become significantly cytotoxic after primary in vitro sensitization to FBL and 
noncuhured  spleen  cells  from  mice  immunized  to  FBL  in  vivo  were  not  directly 
cytotoxic to  tumor  (Table  I).  However,  cytotoxic reactivity  was  readily  detectable 
after  5  d  in  vitro  sensitization  of CBF1  cells  previously  sensitized  in  vivo  to  FBL. P.  D.  GREENBERG,  M.  A.  CHEEVER,  AND  A.  FEFER 
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Cytotoxicity generation culture* 
Responder  Stimulator 
Treatment of effector 
cells:[: 
Percent specific lysis§ 
B10.G (H-2  q)  FBL (H-2  b) 
Allogeneic response 
CBF  --  None  0 .4 0.1 
CBF  B10.G  None  33 ± 2.0 
CBF  B10.G  C only  31 ± 2.4 
CBF  B10.G  a-Thy-l.2 + C  0 ± 0.6 
CBF  B10.G  a-Lyt-1 + C  25 ±  1.0 
CBF  B10.G  a-Lyt-2 + C  9 ±  1.5 
Syngeneic anti-tumor 
response 
CBF  --  None 
CBF  FBL  None 
CBFaFBL  Not cultured  None 
CBF~,rBL  --  None  0 -1- 0.1 
CBF~FaL  FBL  None  1 .4 0.6 
CBFavnL  FBL  C only 
CBF.FBL  FBL  a-Thy-l.2 + C 
CBF,,vBL  FBL  a-Lyt-1 + C 
CBF~FBL  FBL  a-Lyt-2 + C 
0+0.6 
2± 1.5 
2±0.6 
5-4 1.9 
0-1-0.3 
3-1-2.1 
53 .4 6.5 
50 ± 5.9 
5± 1.8 
27:1:2.7 
11 .43.5 
* 60 ×  106 responder cells derived from normal unprimed CBF1 mice (CBF) or mice primed and boosted 
in vivo with irradiated FBL (CBF,  vBL) were cultured with  15 X l0  s irradiated allogeneic B10.G spleen 
ceils or 3 ×  l0  s irradiated FBL tumor cells. 
:~ After 5 d culture, the potential effector cells were harvested. Before testing for cytotoxicity, specific cell 
subpopulations were depleted by incubating these cells with the denoted monoclonal antibody and C. 
§ Cytotoxicity of potential effector populations was measured in a 4-h CRA with labeled concanavalin  A- 
induced B10.G spleen cell blast targets or FBL tumor cells at an effector:target ratio of 20:1. The results 
are the mean cytotoxicities ± SE of four experiments. 
Treatment  of the  effector cells with  either a-Thy-1.2 or a-Lyt-2 and  C  eliminated 
most  cytotoxicity, whereas  ~50%  remained after depletion of Lyt-1 + cells. Thus,  as 
defined  functionally,  the  CTL  to  syngeneic  FBL  tumor  were  most  likely  of two 
phenotypes, Lyt-l-2  + and Lyt-l+2  +. Alternatively, the CTL could be only of the Lyt- 
1-2  +  phenotype,  but  this  would  require  that  Lyt-l+2  +  cytotoxic  precursor  cells 
differentiate to  Lyt-l-2  +  CTL  during  the  4-h  assay,  and  would  operationally still 
yield similar results in the therapy studies using cytotoxic depletion ofsubpopulations. 
Thus,  these monoclonal antibodies characterize CTL with Lyt phenotypes similar to 
that expected with conventional alloantisera (11-17). 
The efficacy of adoptive immunotherapy with these T  lymphocyte subpopulations 
was examined. CBFI mice were inoculated intraperitoneally with 5  ×  106 FBL-3 on 
day 0. On day 5, when  the tumor has already disseminated to peripheral blood and 
spleen (6), mice were treated with ACIT, CY followed by spleen cells from CBF1 mice 
that  had been  primed and boosted in vivo with irradiated FBL-3, a  regimen shown 
to  induce  specific  immunity  to  this  tumor  (8).  The  spleen  cells were  used  either 
directly or after depletion of subpopulations by C  and monoclonal antibody to Thy- 
1.2,  Lyt-1, or Lyt-2 antigen.  The  cumulative results of six experiments with  immu- 
notherapy using 5  ×  106 donor cells are shown  in Fig.  1.  Mice receiving no therapy 
died by day  19, and therapy with CY alone prolonged median survival time to day 
26, but  all mice died of progressive tumor. Therapy on day 5  without  CY and with 956 
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FIo.  1.  In vivo efficacy  ofT cell subpopulations in ACIT of FBL. CBF1 mice were inoculated with 
5  ×  10  6 FBL intraperitoneally on day 0,  and left  untreated  (  , no therapy), treated on day 5 
with cyclophosphamide (  ....  , CY alone), or treated  with CY plus 5  ×  10  6 CBF~ donor cells 
obtained either from normal nonimmune CBFl mice (- -, CBF,o~m~a), or mice that had been primed 
and boosted in vivo with irradiated FBL. Donor immune spleen cells were used either unseparated 
(  ..... , CBF,FBL) or after depletion of subpopulations by in vitro incubation before adoptive transfer 
with C  and antibody to Thy-l.2 ( .... , [CBF=vBL]a-Thy-I.2),  Lyt-1  (--.--, [CBF=FBL]a-Lyt-1), or 
Lyt  2  (  ,  [CBF,,FBL]a-Lyt-2).  Fractions represent  the  number of mice surviving in  the  total 
cumulative group from six experiments. 
only normal  CBF1 cells or CBF1 cells immune to FBL-3 had  no effect on survival 
(curves not shown), and therapy on day 5 with CY plus normal cells yielded the same 
results as therapy with CY alone.  However, therapy with CY plus cells immune to 
FBL prolonged  survival  and  cured  34  of 48  mice.  Depletion  of T  cells  from  the 
immune  population  by  in  vitro treatment  with  a-Thy-l.2 and  C  before adoptive 
transfer abrogated most of the therapeutic effect, with only 3 of 48 mice alive at day 
80, thus confirming the T  cell nature of the major effector cell for chemoimmuno- 
therapy• Depletion of Lyt-1  + cells, which permits persistence of only Lyt-1-2  + T  cells, 
produced similar results with only 8 of 48 mice alive at day 80. In contrast, immune 
cells  depleted  of Lyt-2  +  cells,  which  permits  persistence of only Lyt-l+2  -  T  cells, 
retained most of the therapeutic potential of the initial unseparated population, with 
24 of 48 mice tumor free at day 80. Thus, the major therapeutic effect provided by 
adoptive transfer of immune spleen cells appeared to require the presence of Lyt-1  +2- 
T  cells. 
Although  a-Lyt-2  antibody  was  more  effective in  removing  CTL  to  syngeneic 
tumor than a-Lyt-1  antibody, ACIT was  more negatively affected by depletion of 
Lyt-1  + than Lyt-2  + cells.  Thus, other noncytotoxic functions of the Lyt-1  + subpopu- 
lation must be important in immunotherapy. Lyt-1+2  - T cells, or their products, have 
been shown to promote differentiation and proliferation of CTL precursors (19-21). 
Because previous studies have demonstrated that adoptively transferred immune cells 
must proliferate in the host to be effective in ACIT (5), we examined whether Lyt-1  + 
cells  can  provide an  amplifier  function in  the  generation  of CTL to  FBL tumor• 
Therefore, the generation of CTL in standard MLC and MLTC of unseparated CBF1 
spleen cells was compared with cultures of CBF1 spleen cells depleted of Lyt-1  + cells P.  D.  GREENBERG,  M.  A.  CHEEVER,  AND  A.  FEFER  957 
before  in  vitro  sensitization  and  to  such  Lyt-1 +  cell-depleted  cultures  to  which  a 
supernate  containing  IL-2,  a  T  cell growth  factor produced  by Lyt-l÷2 -  T  cells  (19, 
20),  was  added  at  the  initiation  of culture  as  described  in  Materials  and  Methods. 
This  factor has been  shown  to  reconstitute  the amplifier  function  provided  by  Lyt- 
1+2  -  cells  in  the  generation  of  cytotoxic  responses  (20).  Using  this  method,  the 
generation of cytotoxic responses to alloantigens and syngeneic tumors  was examined 
(Table II). Unseparated  cells generated  significant cytotoxicity, and  depletion of Lyt- 
1  + cells before in vitro sensitization prevented  the generation  of alloreactive cytotoxic 
cells.  However,  supplementation  of Lyt-l+-depleted  cell cultures  with  IL-2  restored 
most of the cytotoxic reactivity detected in nondepleted  cultures. These results suggest 
that  IL-2 adequately  reconstituted  the amplifier function eliminated  by depletion  of 
the Lyt-1 + population.  The  small diminution  of cytotoxicity could reflect elimination 
of a  minor  fraction  of CTL  precursors  because  alloreactive  CTL  were  shown  to  be 
predominantly  of the  Lyt-l-2 +  phenotype  (Table  I).  The  generation  of cytotoxicity 
TABLE  II 
Amplification by IL-2 of CTL Responses in Populations Depleted of Lyt-I ÷ Cells 
Cytotoxicity generation culture* 
Responder 
Percent specific lysis§ 
Addition to 
Precuhure treatment  cuhure~  Stimulator  AKR (H-2  k)  FBL (H-2  b)  of responder cells 
Allogeneic response 
CBF  None  --  0 ±  1.7  0 ±  0.5 
CBF  None  AKR  25 ±  2.5  0 ±  0.5 
CBF  a-Lyt-1 +  C  --  0 +  0.3 
CBF  a-Lyt-1 +  C  AKR  1 +  1.2 
CBF  a-Lyt-I +  C  --  IL-2  2 -t- 0.4  0 ±  0.3 
CBF  a-Lyt-I +  C  AKR  IL-2  20 +  1.4  1 +  0.6 
Syngeneic anti-tumor 
response 
CBF  None  --  0 ±  1.7  0 ±  0.5 
CBF  None  FBL  0 +  1.1  0 ±  0.1 
CBF  a-Lyt-t +  C  --  0 ±  0.3 
CBF  a-Lyt-1 +  C  FBL  0 ±  0.1 
CBF  a-Lyt-1 +  C  --  IL-2  2 ±  0.4  0 ±  0.3 
CBF  a-Lyt-1 +  C  FBL  IL-2  2 ±  0.9  0 ±  0.6 
CBF,FBL  None  --  0 ±  0.5  0 ±  0.5 
CBF,FBL  None  FBL  0 ±  0.7  27 ±  0.1 
CBF~FBL  a-Lyt-1 +  C  --  0 ±  0.6 
CBF~pBL  a-Lyt-1 4- C  FBL  2 ±  0.4 
CBFaFBL  a-Lyt-1 +  C  --  IL-2  1 ±  0.9  0 ±  0.3 
CBF~F~L  a-Lyt-1 +  C  FBL  IL-2  0 ±  0.9  9 ±  0.8 
* Responder cells, derived from normal unprimed CBFI mice (CBF) or mice primed and boosted in vivo 
with irradiated FBL (CBFoFBL), were either used directly without pretreatment, or were depleted of Lyt- 
1  + cells by incubation with a-Lyt-1 and C before in vitro sensitization. These cells were washed and then 
placed into culture with irradiated allogeneie AKR spleen cells or irradiated FBL at responder:stimulator 
ratios of 4:1 and 20:1, respectively. 
Partially purified supernates containing IL-2 were added to the designated responder-stimulator combi- 
nations at the initiation of 5-d culture at a final dilution of 1:10. 
§ After 5 d  culture, effector cells were harvested and washed. Cytotoxicity was measured in a  4-h CRA 
with labeled concanavalin A-induced AKR spleen cell blast targets or FBL tumor cells at an effector to 
target ratio of 20:1. The results are the mean cytotoxicities +  SE of triplicate determinations. 958  ERADICATION  OF  LEUKEMIA  WITH  Lyt-l÷2  -  T  CELLS 
promoted by IL-2 was antigen specific in that it required the presence of alloantigen 
during sensitization and was specific for the allogeneic target. 
The cytotoxic response to syngeneic tumor was similarly assessed  (Table II).  No 
significant  cytotoxicity was  generated  by primary  in  vitro sensitization,  including 
those cell cultures that  had  been  depleted of Lyt-1  + cells  and  supplemented  with 
IL-2.  This  is  consistent  with  a  relative  absence  of Lyt-l-2  +  CTL  precursors  to 
syngeneic tumor in unprimed populations. In vitro sensitization of CBFa cells previ- 
ously immunized in vivo to FBL induced a strong cytotoxic response to the syngeneic 
tumor target. Depletion of Lyt-1  + cells before in vitro culture prevented the generation 
of a significant cytotoxic response, and the addition of IL-2 to these cultures permitted 
only partial restoration of cytotoxicity. The cytotoxicity generated in the presence of 
IL-2  was  specific  for the  tumor  target,  and  required  that  the  cells  be  previously 
immunized to FBL in vivo and cultured with FBL in vitro. The ability of IL-2 to 
restore only a  fraction of the cytotoxicity to FBL generated in cultures that had not 
been depleted of Lyt-1  + cells is consistent with the results in Table I, which demon- 
strated  that  unlike  alloreactive  CTL,  a  significant  fraction  of CTL  and/or  CTL 
precursors to syngeneic tumors are eliminated by a-Lyt-1 and C.  However, despite 
this limitation, which resulted in the generation of only low levels of cytotoxicity, the 
results suggest that  Lyt-1  + cells, or a  product derived from these cells, can augment 
the  in  vitro  generation  of cytotoxic responses  to  syngeneic  tumor.  Perhaps  more 
important, depletion of Lyt-1  + cells prevented the generation of significant cytotox- 
icity. Thus, Lyt-1  + cells that were shown to be critical for efficacy in immunotherapy 
may similarly be required in vivo to permit sufficient expression and  expansion of 
cytotoxic cells to mediate a significant anti-tumor effect. 
Discussion 
The  results  demonstrate  that  the  predominant  donor  effector cell  required  for 
eradication of advanced disseminated leukemia by ACIT is an immune Lyt-l+2  -  T 
cell that is not cytolytic in vitro. Immune cells depleted of Lyt-2  ÷ cells, such that the 
only donor T cells remaining were of the Lyt-1  +2- phenotype, were nearly as effective 
in ACIT as unselected cells, suggesting that other donor T  cell subsets do not provide 
an  essential  contribution.  Moreover, the  potential  therapeutic efficacy of immune 
cells was ablated nearly as completely by depletion of Lyt-1  ÷ cells as by depletion of 
all T cells. The small residual anti-tumor effect still evident after treatment of immune 
cells with a-Thy-l.2 and  C  probably reflected incomplete T  cell  removal because 
previous studies have demonstrated that removal of neither B cells nor macrophages 
diminished the in vivo efficacy of the effector population  (7). Thus, although other 
subpopulations may also participate, donor Lyt-l+2  -  T  cells are necessary to mediate 
the major in vivo anti-tumor effect observed in ACIT after adoptive transfer. 
The T  cell subsets analyzed in ACIT were defined operationally by susceptibility 
to lysis by monoclonal antibody to Lyt antigens and C. Immunofluorescent analysis 
of  Lyt  antigen  expression  has  suggested  that  such  absolute  distinctions  of  Lyt 
phenotypes are somewhat artificial (i.e., all T  cells express some Lyt-1 antigen), and 
has implied that the source and titer of antibody and C can influence the separation 
of subsets  (22, 23). Therefore, the effect of the reagents used in our studies on well- 
defined in vitro T  cell functions was analyzed. Alloreactive CTL were predominantly 
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were of both  the  Lyt-l-2  +  and  Lyt-l+2  +  phenotypes.  This representation  of Lyt-1 
antigen on a  minor fraction of alloreactive CTL and on a  larger fraction of CTL to 
syngeneic tumor is similar to reports using conventional  a-Lyt alloantisera  (13,  14, 
23).  More important, these studies confirm that the Lyt-l+2  -  cell active in ACIT is 
distinct  from the major effector cell mediating in vitro tumor lysis. 
The in vivo activity of T  cell subsets against syngeneic tumors has been analyzed 
in only a  few models. Tumor neutralization of a syngeneic sarcoma, in which tumor 
cells and immune cells were mixed before inoculation into the host, required Lyt-1 +2 + 
effeetor cells  (24), which were also required  for in vitro cytolysis of this tumor in a 
microcytotoxicity assay  (13).  Prevention of outgrowth  of a  Moloney lymphoma, in 
which  immune  cells  were  inoculated  before the  tumor,  required  Lyt-l-2  ÷  effector 
cells, which were also responsible for in vitro lysis of this tumor (25). Previous studies 
from our laboratory have suggested that the immunologic requirements for efficacy 
in ACIT of established FBL tumor differ from those for tumor neutralization  (9), but 
do not readily explain why CTL should appear more important in neutralization and 
prevention of tumor than  in  therapy of established  tumor. Also of note is a  recent 
analysis of adoptive immunotherapy of an established vascular Moloney sarcoma in 
preirradiated rats that has identified an effector cell with some characteristics similar 
to those of the effector cell we identified for ACIT of disseminated leukemia. Although 
T  cell  subsets  are  less  well characterized  in  the  rat  than  in  the  mouse,  the  subset 
required for effective immunotherapy in vivo was not cytolytic to tumor in vitro (4). 
The potential mechanisms by which  Lyt-l+2  -  T  cells can promote in vivo eradi- 
cation of established FBL tumor must reflect one or several of the T  effector functions 
characterized  by this subset,  helper cells  for antibody responses,  initiators  of DTH 
responses, and amplifiers of CTL responses. A  helper function to enhance antibody 
responses seems least likely, because immunotherapy of established tumors by infusion 
of antibody  has  generally  been  unsuccessful  (reviewed  in  1).  Additionally,  T  cell- 
deficient  "B" mice (i.e.,  thymectomized, lethally irradiated  mice reconstituted with 
syngeneic T-depleted bone marrow) were not protected from lethal outgrowth of an 
inoculated Moloney-induced tumor of C57BL/6 origin (MBL) by previous adoptive 
transfer of Lyt-l+2  -  T  cells immune to MBL lymphoma, which contained helper T 
cells for an antibody response to this virus-induced tumor (25). 
A second mechanism by which Lyt-l+2  -  cells could influence tumor rejection is by 
initiation ofa DTH response. Sensitization of A/J mice with a syngeneic fibrosarcoma 
induces  T  cells  that  can  adoptively  transfer  a  tumor-specific  DTH  response  to  a 
secondary host  (26).  However,  the  role of such  T  effector cells  in  the  rejection  of 
established tumors has not been demonstrated. Although regressing sarcomas contain 
inflammatory  cells  that  could  reflect  an  ongoing  DTH  response,  these  regressing 
tumors also contain  directly cytolytic T  cells as well as primed tumor-specific CTL 
precursors  that  can  be expanded  to  produce  increased  numbers  of CTL  (21,  27). 
Moreover, inoculation of immune Lyt-1  +2- T  cells into "B" mice, a situation in which 
potential  DTH effectors are present  and CTL effectors are absent, did not  prevent 
lethal outgrowth of a subsequent inoculum of MBL tumor (25). Thus, the importance 
ofDTH effectors in ACIT of FBL, a tumor antigenieally similar to MBL (28), remains 
uncertain. 
The last alternative, that Lyt-l+2  -  cells provide an amplifier function in the host, 
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have been shown to augment generation of tumor-specific CTL in vitro and enhance 
neutralization of tumor in vivo (29). If the critical immune cell for ACIT of  established 
tumor is an amplifier cell, one might predict that tumor eradication would be delayed 
for a period of time after adoptive transfer, during which time sufficient expansion of 
the pool of cytotoxic effector cells occurred. Bioassay experiments examining the time- 
course of tumor elimination in ACIT have demonstrated that there is in fact a period 
of tumor  growth  after  ACIT  before  the  tumor  is  eliminated  (6).  Furthermore, 
immunosuppression of the host 2 wk after ACIT with anti-thymocyte serum results in 
lethal tumor outgrowth (6).  Similar delays in tumor eradication have been observed 
in adoptive immunotherapy of established fibrosarcomas in mice and rats; measurable 
tumor growth continued for 1-2 wk after transfer of immune cells before the onset of 
tumor rejection became apparent (3, 4). 
Immune  cells  depleted  of Lyt-1  +  cells  were  only minimally  effective in  ACIT, 
despite the presence of CTL and CTL precursors. This may reflect a predominantly 
quantitative phenomenon, in that an inadequate number of CTL may be present in 
the  infusate  to eradicate  the  tumor,  and  the  CTL provided may be  incapable  of 
sufficient expansion  in  the  absence of amplifier  cells.  In  addition,  Lyt-l-2  +  CTL 
memory cells appear to have a short functional lifespan (16, 25, 30), and thus may be 
unable  to  mediate  a  prolonged  in  vivo  anti-tumor  effect.  Therefore,  continued 
generation of cytolytic effector cells in  vivo might require the infusion of Lyt-l+2  - 
amplifier cells, which appear to have a long lifespan (16, 25, 30), and the presence of 
Lyt-l+2  ÷  CTL  precursors.  The  limited  efficacy of the  Lyt-l-2  ÷  subpopulation  in 
therapy  might  also  reflect  in  part  a  relative  inability  of adoptively  transferred 
cytotoxic spleen ceils to traffic to sites of disseminated tumor in the host.  However, 
although the homing patterns of adoptively transferred immune T cell subpopulations 
has not been well described, transferred Lyt-1-2  + cells have been shown to be capable 
of homing to and eliminating a small localized subcutaneous MBL tumor (25). 
Immune cells depleted of Lyt-2  ÷ cells remained effective in ACIT. If the resulting 
Lyt-l+2  -  cells operate in vivo by providing an amplifier function for CTL induction, 
the host must be capable of providing the necessary CTL precursors. The potential 
for a  positive host contribution to the outcome of ACIT is very provocative. IL-2, 
which augmented the in vitro generation of CTL to FBL tumor, has been shown to 
induce in vitro differentiation and proliferation of CTL (19-21). Moreover, inocula- 
tion of IL-2 into nude mice can induce in vivo production of antigen-specific CTL 
(20,  31).  Although  normal  mouse  serum  appears  to  contain  an  inhibitor  of IL-2 
activity, local injection of IL-2 into a footpad augmented in vivo generation of CTL 
to trinitrophenyl-modified cells in the draining lymph node (20). Thus, it is conceiv- 
able that under the proper conditions, the requirement for immune Lyt-l+2  -  T  cells 
in  ACIT  could  be  circumvented  by  the  infusion  of sufficient  IL-2  to  promote 
expansion of host precursor CTL. Such a therapeutic approach would have obvious 
practical implications. 
Summary 
The phenotype of T  cells therapeutically effective in immunotherapy of advanced 
Friend  virus-induced  (FBL)  leukemia  in  vivo and  cytotoxic to  FBL  in  vitro was 
determined. Mice bearing disseminated FBL leukemia were successfully treated by a 
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phocytes. Therapeutic efficacy was largely dependent  on the presence of Lyt-l+2  -  T 
cells  in  the  transferred  cells,  whereas  cells  cytotoxic  to  FBL  tumor  in  vitro  were 
derived from the Lyt-1+2  + and Lyt-1-2  + subsets. Thus, the predominate cell required 
to eradicate  tumor in adoptive chemoimmunotherapy was not cytolytic to tumor in 
vitro. 
Potentially,  the Lyt-l+2  -  cell may operate in vivo as an amplifier cell rather than 
by a  direct anti-tumor effect. Elimination of the Lyt-1 + population with a-Lyt-1 and 
complement prevented  the generation of significant cytotoxic responses during both 
primary  in  vitro  sensitization  to  alloantigens  and  in  vitro  sensitization  of tumor- 
primed cells. The capacity of the Lyt-1 ÷ cell-depleted population to generate cytotoxic 
responses  was  partially  reconstituted  by  addition,  at  the  initiation  of culture,  of 
interleukin  2, a  T  cell growth factor derived  from Lyt-l+2  -  T  cells. Thus the Lyt-1 + 
population contained helper-amplifier T  cells required  for the in vitro generation of 
eytotoxic T  lymphocytes (CTL). 
Adoptive chemoimmunotherapy with immune cells depleted of Lyt-2  + cells, which 
contain the CTL and CTL precursors, were nearly as effective in vivo as unseparated 
immune cells.  If the remaining effector cells  (i.e.,  Lyt-l+2  -  T  cells)  function in vivo 
predominantly  as  amplifier  cells,  then  the  tumor-bearing  host  must  be  capable  of 
making a  positive contribution to the outcome of therapy. 
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